Woori Financial Group Details Share Exchange for Tongyang Life Insurance, Outlines 1.19% Dilution

summarizeSummary

Woori Financial Group has released a detailed Q&A document outlining the terms of its share exchange to acquire the remaining shares of Tongyang Life Insurance, which will result in approximately 1.19% dilution for existing shareholders.

check_boxKey Events

• Full Acquisition of Subsidiary Detailed

  Woori Financial Group will acquire all remaining shares of its subsidiary, Tongyang Life Insurance, via a comprehensive share exchange, making it a wholly-owned entity.

• Specific Share Exchange Ratio Announced

  Each Tongyang Life Insurance share will be exchanged for 0.2521056 shares of Woori Financial Group, based on market-priced exchange rates (W8,720 for Tongyang Life Insurance and W34,589 for Woori Financial Group).

• 1.19% Share Dilution Expected

  The transaction will result in approximately 1.19% dilution for existing Woori Financial Group shareholders due to the issuance of new common stock.

• Strategic Rationale for Acquisition

  The acquisition aims to bolster management efficiency, strengthen the insurance business, and reduce costs associated with the concurrent parent-subsidiary listing status.

auto_awesomeAnalysis

This filing provides comprehensive details regarding Woori Financial Group's strategic move to fully acquire its subsidiary, Tongyang Life Insurance, through a share exchange. This follows previous 6-K filings on April 24, 2026, which announced the intent of this transaction. While the share issuance will result in approximately 1.19% dilution for current shareholders, the company emphasizes long-term benefits such as enhanced management efficiency, strengthened insurance business, and reduced operational costs. The detailed schedule, specific exchange ratio, and shareholder protection measures, including review by an independent committee and accounting firm, aim to ensure fairness and transparency in this significant M&A event, which is part of the company's broader strategic consolidation efforts. Investors should monitor the shareholder dissent period, which runs from May 6 to May 13, 2026, and the final approval process.